Evaluation of the efficacy and safety of omalizumab in the treatment of pregnant patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study (ChiCTR) - Oct 16, 2026 - P=N/A | N=48 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University
New trial • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
|